A major development in the 2026 ESC Heart Failure Guidelines is the move toward a simpler EF cutoff: HF with LVEF <50% versus HF with LVEF ≥50% — moving away from the traditional three-way separation of HFrEF, HFmrEF, and HFpEF. And within this new framework, the guidelines send another clear message: AF in heart failure is no longer just a rate-control problem. ➡️ When #AFib is driving LV dysfunction, restoring sinus rhythm is recommended, with catheter ablation playing a central role. ➡️ In selected patients with #AFib and HFrEF, catheter ablation should be considered to reduce heart failure hospitalization and improve survival. ➡️ In HFpEF, the evidence gap remains, and treatment decisions should be individualized. The guidelines also highlight an old friend: digoxin. Once pushed to the sidelines, it again has a role in rate control for patients with AF and heart failure, particularly when other agents are ineffective, contraindicated, or poorly tolerated. The key message for patients is simple: AF may be a driver of heart failure, not merely a consequence. Recognizing and treating it early could improve symptoms and outcomes. The next frontier is clear: can eliminating AF change the natural history of HFpEF? #CASTLEHFpEF #ESC2026 #ESCCongress #AtrialFibrillation #HeartFailure #HFrEF #HFpEF #Ablation @lamcardio @Phiso_de @chris_sohns @shivkumarmd @S_NarayanMD @drjohnm @TulaneTriad @TulaneHeart